News coverage about Adaptimmune Therapeutics (NASDAQ:ADAP) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Adaptimmune Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.6467418045023 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
Adaptimmune Therapeutics (ADAP) opened at $7.86 on Wednesday. Adaptimmune Therapeutics has a 52 week low of $3.76 and a 52 week high of $9.29.
ADAP has been the topic of several research analyst reports. ValuEngine cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. SunTrust Banks reissued a “buy” rating and issued a $10.00 price objective on shares of Adaptimmune Therapeutics in a research note on Friday, November 10th. Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. TheStreet raised Adaptimmune Therapeutics from a “d” rating to a “c” rating in a research report on Thursday, November 2nd. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $15.00 target price on shares of Adaptimmune Therapeutics in a research report on Friday, September 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $11.58.
TRADEMARK VIOLATION WARNING: This news story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-adaptimmune-therapeutics-adap-share-price.html.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.